Population-based estimate of the use of intermittent androgen deprivation therapy in prostate cancer patients in Catalonia, Spain.

José A CorderoGemma SanchoXavier Bonfill

Published in: Pharmacoepidemiology and drug safety (2019)

This study confirms the validity of the method developed to estimate IAD use based on electronic pharmacy dispensation data. Given the large potential clinical and economic benefits that greater use of IAD could provide, future studies are needed to confirm these findings and to identify new strategies to increase the use of IAD.

Keyphrases

prostate cancer
end stage renal disease
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
stem cells
radical prostatectomy
electronic health record
machine learning
risk assessment
patient reported outcomes
big data
human health
smoking cessation